Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer ; volume:7 ; number:1 ; day:15 ; month:4 ; year:2007 ; pages:1-5 ; date:12.2007
BMC cancer ; 7, Heft 1 (15.4.2007), 1-5, 12.2007
- Urheber
-
Samaritani, Riccardo
- Beteiligte Personen und Organisationen
-
Corrado, Giacomo
Vizza, Enrico
Sbiroli, Carlo
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-7-65
- URN
-
urn:nbn:de:1111-2016030344162
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
31.01.0008, 09:03 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Samaritani, Riccardo
- Corrado, Giacomo
- Vizza, Enrico
- Sbiroli, Carlo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Chemotherapy for Advanced Epithelial Ovarian Cancer
Intra Peritoneal Chemotherapy in Epithelial Ovarian Cancers
Adjuvant Chemotherapy for Epithelial Ovarian Cancer (EOC)
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Study
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience
Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience
Rapidly Progressive Pleuro-parenchymal Fibroelastosis Secondary to Cyclophosphamide Chemotherapy
Cyclophosphamide in Ovarian Cancer Subtypes: Time for a Comeback
Extended adverse effects of cyclophosphamide on mouse ovarian function
Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients
Palliative chemotherapy: oxymoron or misunderstanding?
Chemotherapy for Advanced Epithelial Ovarian Cancer
Intra Peritoneal Chemotherapy in Epithelial Ovarian Cancers
Adjuvant Chemotherapy for Epithelial Ovarian Cancer (EOC)
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Study
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience
Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience
Rapidly Progressive Pleuro-parenchymal Fibroelastosis Secondary to Cyclophosphamide Chemotherapy
Cyclophosphamide in Ovarian Cancer Subtypes: Time for a Comeback
Extended adverse effects of cyclophosphamide on mouse ovarian function
Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients
Palliative chemotherapy: oxymoron or misunderstanding?
Chemotherapy for Advanced Epithelial Ovarian Cancer
Intra Peritoneal Chemotherapy in Epithelial Ovarian Cancers
Adjuvant Chemotherapy for Epithelial Ovarian Cancer (EOC)
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Study
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience
Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience
Rapidly Progressive Pleuro-parenchymal Fibroelastosis Secondary to Cyclophosphamide Chemotherapy
Cyclophosphamide in Ovarian Cancer Subtypes: Time for a Comeback
Extended adverse effects of cyclophosphamide on mouse ovarian function
Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients